OBJECTIVES: Research development regarding better dengue vaccines is still conducted for two decades. Live attenuated is one of the vaccine types, with one brand already approved by FDA, and DENVax is another in the pipeline. The research aims to determine the efficacy, immunogenicity, and safety of DENVax.

METHODS: A systematic review and meta-analysis were conducted using randomized clinical trials (RCT) published between 2000 and 2022 identified in the EBSCO, Embase, PubMed, and Web of Science. The study protocol was registered in PROSPERO with ID CRD42022334208.

RESULTS: Eight RCTs with about ten thousand participants were included in this research. The efficacy showed different results in adults and children, as well as immunogenicity. The researchers did not find serious safety issues in the included papers.

CONCLUSIONS: DENVax showed efficacy and immunogenicity in adults and children, but further studies are required to establish long-term effectiveness. DENVax was also well tolerated against dengue.